Formulary guidance and transparency from P&T to point of care

Perspectives on Top Highly Managed Classes

Posted by Matt Breese on Sep 29, 2015

Find me on:


The industry spotlight continues to focus on pharmaceutical products in highly managed therapeutic classes. A recent article from CNN analyzes a handful of the most expensive market baskets to better understand the underlying drivers of pharmaceutical pricing and coverage. Current news around pharmaceutical manufacturer activity and how payers are covering these highly managed classes paints an even more vibrant picture.

The healthcare industry is looking optimistically at the future of products for Diabetes based on signs of pharmaceutical manufacturers’ willingness to partner with technology firms to deliver innovative treatments. As an example, Sanofi and Google are partnering to analyze medication regimens and patient utilization of sensor devices with the goal of developing more advanced technologies that reduce barriers to quality care. Another study from the FASEB Journal provides new insight into treating patients with both cancer and Diabetes, including advancements in the understanding of how high blood sugar promotes cancer growth.

New HIV cure research looks to combination treatments as the most promising path forward. Some experts believe that a shift from the traditional single-therapy development model to more advanced compound pharmaceuticals is well underway and will continue to impact the HIV drug landscape.

During recent years, Hepatitis C treatments like Sovaldi and Harvoni are proving to be extremely effective. However, patient access to these products is a concern as emphasized by the story of Laura Bush, a provider out of New Mexico, who spends most of her time filing prior authorization forms and writing appeal letters between seeing patients. Another publication describes the cost challenges faced by state Medicaid and the Department of Corrections as they attempt to administer a treatment to low-income populations that runs about $70,000 per 12-week cycle.

Oncology is getting a facelift with collaboration from pharma, providers and other industry influencers. A piece from PharmaPhorum summarizes key oncology digital influencers and how pharma’s trending adoption of modern channels is impacting cancer care. From the provider perspective, oncologists are looking for more streamlined access to current clinical data and EHR interoperability for more efficient care for cancer patients.

When it comes to highly managed antipsychotic treatments, pharma continues to increase the variety of options available. The recent FDA approval of Vraylar, indicated for both Schizophrenia and Bipolar Disorder, introduces a fresh face to a market basket saturated with seasoned products.

Check out our Twitter handle for more news and trends on highly managed classes.

Follow MMIT on Twitter

Topics: Specialty, Market Access